Abstract 15P
Background
Estrogen plays a pivotal role in the development of breast cancer. Previous studies have shown that estrogen enhances cell proliferation via regulating its target gene expression in human breast cancer MCF-7 cell line. Although the effect of estrogen on the carcinogenesis in breast, the effects of pregnenolone (PG), an inactive precursor of estrogen, on MCF-7 cells or breast cancer have not been adequately explored. PG is a precursor in the biosynthesis of most of the steroid hormones containing estrogen. This investigation aimed to evaluate the effects of PG on cell proliferation and cell cycle-related protein expression.
Methods
We used Michigan Cancer Foundation-7 cell (MCF-7 cell) line, to assess the impact of PG on the carcinogenicity of breast cancer cells. We examined cell proliferation, survival rate and mobility using Bromodeoxyuridine, MTT assay and western blot. To reveal the mechanism of PG, we performed RNA seq after treatment of PG in the MCF-7 cells and transfection using siRNA of estrogen receptor and ERE luciferase vector.
Results
PG increased cell proliferation, viability, mobility, and the expression of proteins associated with the cell cycle, such as CDK2, CDK4, and Cyclin D1. We elucidated the carcinogenic mechanism of PG. Through protein-ligand docking energy analysis, we measured the affinity of PG for estrogen receptors (ERs), showing a high affinity for ERα similar to E2. When treated with cyanine 5-conjugated with PG (Cy5-PG), we observed that PG entered the cells within five minutes. Then, activated ERα entered the nucleus, bound to ERE-promoters, and significantly increased the expression of target genes associated with cell proliferation and carcinogenicity, such as pS2 and Ki-67. These results indicate that PG increases the expression of target genes through ERα and thereby affects the carcinogenicity of breast cancer cells.
Conclusions
Our results demonstrate that PG can have a significant impact on the proliferation and migration of ERα-positive breast cancer cells through ERα. Furthermore, the sustained high concentration of PG, unlike E2 which rapidly decreases after menopause, is strongly associated with the development of breast cancer. Therefore, PG has the potential to serve as a risk factor and diagnostic biomarker for breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract